ZyVersa Therapeutics shares are trading higher after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities...
ZyVersa Therapeutics, Inc. - Common Stock -4.35%
ZyVersa Therapeutics, Inc. - Common Stock ZVSA | 2.20 | -4.35% |
ZyVersa Therapeutics shares are trading higher after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.